Lennox-Gastaut Syndrome - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Lennox-Gastaut Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Lennox-Gastaut Syndrome - Pipeline Review, H2 2014', provides an overview of the Lennox-Gastaut Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lennox-Gastaut Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lennox-Gastaut Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lennox-Gastaut Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lennox-Gastaut Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lennox-Gastaut Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lennox-Gastaut Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lennox-Gastaut Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Lennox-Gastaut Syndrome - Overview 7
Pipeline Products for Lennox-Gastaut Syndrome - Comparative Analysis 8
Lennox-Gastaut Syndrome - Therapeutics under Development by Companies 9
Lennox-Gastaut Syndrome - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Lennox-Gastaut Syndrome - Products under Development by Companies 12
Lennox-Gastaut Syndrome - Companies Involved in Therapeutics Development 13
Eisai Co., Ltd. 13
GW Pharmaceuticals plc 14
INSYS Therapeutics, Inc. 15
Novartis AG 16
Lennox-Gastaut Syndrome - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 24
cannabidiol - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Epidiolex - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
GWP-42003-P - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
perampanel - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
rufinamide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Lennox-Gastaut Syndrome - Recent Pipeline Updates 33
Lennox-Gastaut Syndrome - Product Development Milestones 41
Featured News & Press Releases 41
Dec 05, 2014: Eisai Presents New Data on Rufinamide at the 68th Annual American Epilepsy Society Meeting 41
Oct 15, 2014: U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome 41
Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome 42
May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome 43
Feb 28, 2014: GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex in the Treatment of Lennox-Gastaut Syndrome 44
Jul 26, 2013: Mylan Confirms First-to-File Patent Challenge Relating to BANZEL 44
May 28, 2013: Eisai To Launch Antiepileptic Agent Inovelon Tablets 100mg And 200mg In Japan 45
Mar 25, 2013: Eisai Receives Manufacturing And Marketing Authorization For Antiepileptic Agent Inovelon In Japan 45
Jan 02, 2013: Eisai Launches Inovelon Oral Suspension Formulation In Spain 46
Nov 06, 2012: All Wales Strategic Medical Group And Scottish Medicines Consortium Accept Use Of Inovelon Drinkable, Child-friendly Formulation 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products under Development for Lennox-Gastaut Syndrome, H2 2014 7
Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Lennox-Gastaut Syndrome - Pipeline by Eisai Co., Ltd., H2 2014 13
Lennox-Gastaut Syndrome - Pipeline by GW Pharmaceuticals plc, H2 2014 14
Lennox-Gastaut Syndrome - Pipeline by INSYS Therapeutics, Inc., H2 2014 15
Lennox-Gastaut Syndrome - Pipeline by Novartis AG, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 23
Lennox-Gastaut Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 33